GrowingWithAK
← Back

Nippon India Mutual Fund · #102431

Nippon India Pharma Fund - Regular Plan - Growth Option

Equity · Sectoral/ Thematic · Regular · Growth

Regular TER: 1.84% · as of

5-year NAV · change the window using the controls in the rolling-returns card below ↓

2021-10-25 → 2026-10-21

min ₹253.79 change +76.3% max ₹576.97

Latest NAV

₹528.6359

as of 2026-10-21 · -0.47% vs 2026-10-19

Earliest NAV in archive

2006-04-03

AMFI archive begins Apr 2006

Worst peak-to-trough drawdown

-47.36%

trough 2008-10-27 (since archive start)

Trailing CAGR vs assigned benchmark

Window Scheme CAGR Benchmark CAGR Excess Period
1y +2.46% — — 2025-10-23 → today · 1.0y
3y +15.62% — — 2023-10-23 → today · 3.0y
5y +12.03% — — 2021-10-22 → today · 5.0y
10y +13.69% — — 2016-10-21 → today · 10.0y

Benchmark assignment is mapped by category and sub-category from public sources. "Since inception (in archive)" uses the earliest NAV in the AMFI archive (April 2006 onward).

Rolling 1-year returns distribution · 1229 daily entry points · last 5 years

Imagine buying this fund on any day in this period and holding for exactly one year. Each bar counts how often that ended with a given return: green bars made money, red bars lost money even after a full year. Taller bar = more common outcome.

0% -15.3% to -12.7%: 32 windows -12.7% to -10.2%: 35 windows -10.2% to -7.6%: 50 windows -7.6% to -5.0%: 50 windows -5.0% to -2.4%: 80 windows -2.4% to +0.1%: 71 windows +0.1% to +2.7%: 47 windows +2.7% to +5.3%: 62 windows +5.3% to +7.8%: 66 windows +7.8% to +10.4%: 81 windows +10.4% to +13.0%: 74 windows +13.0% to +15.6%: 79 windows +15.6% to +18.1%: 49 windows +18.1% to +20.7%: 48 windows +20.7% to +23.3%: 35 windows +23.3% to +25.8%: 44 windows +25.8% to +28.4%: 24 windows +28.4% to +31.0%: 25 windows +31.0% to +33.5%: 21 windows +33.5% to +36.1%: 22 windows +36.1% to +38.7%: 18 windows +38.7% to +41.3%: 14 windows +41.3% to +43.8%: 39 windows +43.8% to +46.4%: 19 windows +46.4% to +49.0%: 29 windows +49.0% to +51.5%: 45 windows +51.5% to +54.1%: 21 windows +54.1% to +56.7%: 13 windows +56.7% to +59.3%: 21 windows +59.3% to +61.8%: 15 windows -15% +62%

Median 1y return

+11.9%

Mean 1y return

+15.7%

Best / worst 1y

+61.8% / -15.3%

Windows positive

74%

5th %ile -10.7%
25th %ile -0.4%
75th %ile +27.3%
95th %ile +52.2%

Longer rolling windows · annualised

Same idea over longer holding periods. Returns are CAGR (annualised) so they're directly comparable to the trailing-CAGR table above.

Period Median Mean Worst Best % positive Windows
3y rolling +18.1% +15.4% -2.1% +30.5% 95% 2463
5y rolling +17.9% +18.6% -1.0% +39.7% 100% 3688
10y rolling +16.9% +17.2% +10.4% +25.0% 100% 2601

Beat-benchmark consistency · vs assigned benchmark, across overlapping windows

Of all the rolling windows we observed, how often did this fund's return exceed the benchmark's over the same window. A higher fraction means more consistent outperformance, but says nothing about future windows.

Period Windows beat Total windows % beat Avg excess
(annualised)
1y rolling 190 590 32% -2.0%
3y rolling 0 99 0% -2.4%

Monthly returns · since inception (Apr 2006)

How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.

Year Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year
2026 -4.3 +5.7 -4.9 +5.6 +3.1 +4.5 +2.2 +2.0 -3.6 -5.6 · · +3.8
2025 -8.9 -5.9 +6.5 +3.3 +1.4 +2.9 +2.3 -4.3 -2.4 +3.2 +1.6 -2.0 -3.3
2024 +6.0 +3.1 -0.2 -0.1 +0.8 +3.2 +9.7 +6.0 +0.8 -1.6 -0.8 +3.2 +34.0
2023 -2.5 -3.2 +1.4 +4.8 +2.1 +9.4 +8.0 +1.2 +1.8 -3.3 +10.9 +4.1 +39.2
2022 -8.7 -2.5 +3.9 -1.0 -6.9 -2.4 +5.4 +0.5 +2.1 +2.7 +0.9 -3.3 -9.9
2021 -3.7 -0.5 +3.2 +10.5 +5.7 +4.5 +1.8 +1.4 -2.4 -2.8 +1.5 +3.3 +23.9
2020 +2.7 -0.2 -7.9 +25.3 +3.6 +1.3 +11.9 +0.8 +5.9 -1.6 +7.1 +6.5 +66.4
2019 +1.4 -2.0 +2.1 +1.4 -6.4 -1.5 -2.2 +1.7 -0.6 +5.8 +2.2 +0.2 +1.7
2018 -0.5 -1.9 -5.1 +7.6 -6.1 +5.8 +2.3 +10.5 -2.1 -1.6 -1.9 -2.1 +3.6
2017 -2.1 +3.4 -0.4 -3.1 -7.3 +5.8 +0.8 -4.9 +4.6 +3.5 +2.4 +5.7 +7.6
2016 -5.8 -6.5 -0.6 +2.2 -1.3 +1.3 +5.7 +1.5 +0.5 +2.2 -2.5 -6.9 -10.6
2015 +3.7 -2.3 +8.1 -4.7 +4.1 -1.9 +5.3 +6.7 +2.2 +2.3 -7.1 +2.7 +19.4
2014 +0.3 +6.5 -2.4 +3.0 -3.0 +11.0 +4.6 +8.4 +10.5 +0.1 +2.9 +0.4 +49.5
2013 -3.9 -4.4 +2.3 +6.0 +2.6 -1.5 +0.4 +1.3 +2.6 +1.7 +5.8 +7.0 +20.9
2012 +6.7 -0.3 +2.1 +4.5 -3.7 +3.8 +3.9 +5.7 +1.6 +0.8 +4.1 +1.6 +34.8
2011 -6.6 -7.4 +7.2 +4.4 +2.8 +1.2 +1.3 -8.5 +0.2 +2.4 -4.9 -2.1 -11.0
2010 -3.5 +2.1 +12.6 +1.8 +1.3 +6.6 -2.5 -1.1 +4.3 +3.3 +0.5 +3.5 +31.9
2009 -11.3 -1.8 +9.5 +4.5 +26.0 +0.7 +12.5 +12.4 +11.7 -0.1 +9.2 +12.2 +118.6
2008 -25.5 +5.3 -8.3 +11.3 -2.1 -7.1 +4.9 +5.4 -8.9 -20.0 -0.6 +13.2 -34.0
2007 +1.3 -5.2 +1.0 +9.4 +10.5 +6.5 +3.3 -5.4 +1.3 +5.7 -5.6 +21.4 +49.8
2006 · · · · -15.5 -10.1 -0.5 +17.1 +5.2 +1.6 +1.3 +1.6 -2.6
Avg -3.3 -0.9 +1.5 +4.8 +0.6 +2.1 +3.8 +2.8 +1.7 +0.2 +1.4 +3.5 +22.8

All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row. The Avg row is the plain average of each column across the years shown (19 complete calendar years in the last column); the running month is left out of it.

Portfolio mix · asset class breakdown as of 2026-09-30

Equity 96.8%
Debt 0.5%
Other / unclassified 2.7%
Equity split: Large 29.7% Mid 39.0% Small 28.0%

Size axis (Style Box) · Large / Mid / Small split of latest disclosed holdings

Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).

  • Large Cap 29.7%
  • Mid Cap 39.0%
  • Small Cap 28.0%
  • Cash & Equivalents 2.7%
  • Unlisted & other equity 0.5%

Index overlap

· vs · share of this fund's AUM that sits in stocks the index also includes

No holdings data yet for this fund.

Top stocks held · 36 holdings as of 2026-09-30 See changes vs previous snapshot →

Stock Sector % of fund
Sun Pharmaceutical Industries Limited Pharmaceuticals & Biotechnology 11.71%
Divi's Laboratories Limited Pharmaceuticals & Biotechnology 7.10%
Lupin Limited Pharmaceuticals & Biotechnology 6.17%
Cipla Limited Pharmaceuticals & Biotechnology 6.01%
Dr. Reddy's Laboratories Limited Pharmaceuticals & Biotechnology 5.45%
Apollo Hospitals Enterprise Limited Healthcare Services 4.89%
Mankind Pharma Limited Pharmaceuticals & Biotechnology 4.38%
Sai Life Sciences Limited Pharmaceuticals & Biotechnology 3.92%
Ajanta Pharma Limited Pharmaceuticals & Biotechnology 3.61%
GlaxoSmithKline Pharmaceuticals Limited Pharmaceuticals & Biotechnology 3.11%
IPCA Laboratories Limited Pharmaceuticals & Biotechnology 2.87%
Max Healthcare Institute Limited Healthcare Services 2.70%
Vijaya Diagnostic Centre Limited Healthcare Services 2.62%
Gland Pharma Limited Pharmaceuticals & Biotechnology 2.53%
MedPlus Health Services Limited Retailing 2.53%
Abbott India Limited Pharmaceuticals & Biotechnology 2.32%
Piramal Pharma Limited Pharmaceuticals & Biotechnology 2.24%
Thyrocare Technologies Limited Healthcare Services 2.24%
Dr. Lal Path Labs Limited Healthcare Services 2.17%
Alkem Laboratories Limited Pharmaceuticals & Biotechnology 1.82%

Sector mix

Healthcare: 97.4% Services: 2.6%
  • Healthcare 97.4%
  • Services 2.6%

Risk metrics, trailing 3y (733 matched daily returns, 2023-10-25 → 2026-10-21)

Sharpe

+0.75

excess return per unit of total volatility

Sortino

+1.07

excess return per unit of downside vol

Calmar

+1.05

CAGR / |max DD| in window

Beta vs benchmark

+0.82

scheme sensitivity to benchmark moves

Tracking error

+5.08%

annualised stdev of (scheme − benchmark)

Up capture

+80.5%

% of benchmark gain captured on up days

Down capture

+80.3%

% of benchmark loss participated in

Risk-free rate assumed 6.0% annualised. Benchmark = Nifty Pharma (assigned by category mapping).

Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.